Paper41999452
Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.
Cetin B and 3 others. Curr Treat Options Oncol, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. Papers, record 41999452. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999452
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Cyclin-Dependent Kinase 4 | Major topic |
| Cyclin-Dependent Kinase 6 | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| Female | |
| Neoplasm Metastasis | |
| Receptors, Estrogen | |
| Receptors, Progesterone | |
| Molecular Targeted Therapy | |
| Drug Resistance, Neoplasm | |
| Biomarkers, Tumor | |
| Treatment Outcome | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Mutation |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3798106 | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. | Science | 1987 | https://conductscience.org/library/papers/3798106 | PubMed |
| 2 | 37019913 | An emerging generation of endocrine therapies in breast cancer: a clinical perspective. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/37019913 | PubMed |
| 3 | 30069049 | Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. | Nature | 2018 | https://conductscience.org/library/papers/30069049 | PubMed |
| 4 | 30462943 | Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30462943 | PubMed |
| 5 | 22010023 | Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/22010023 | PubMed |
| 6 | 39072356 | VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. | Future Oncol | 2024 | https://conductscience.org/library/papers/39072356 | PubMed |
| 7 | 31125586 | Targeting Nuclear Receptors with PROTAC degraders. | Mol Cell Endocrinol | 2019 | https://conductscience.org/library/papers/31125586 | PubMed |
| 8 | 39476340 | Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39476340 | PubMed |
| 9 | 39265124 | Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/39265124 | PubMed |
| 10 | 26122181 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. | Nat Rev Clin Oncol | 2015 | https://conductscience.org/library/papers/26122181 | PubMed |
| 11 | 40068598 | CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. | Cancer Cell | 2025 | https://conductscience.org/library/papers/40068598 | PubMed |
| 12 | 39660834 | Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. | N Engl J Med | 2025 | https://conductscience.org/library/papers/39660834 | PubMed |
| 13 | 38824244 | Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38824244 | PubMed |
| 14 | 34392831 | ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. | Breast Cancer Res | 2021 | https://conductscience.org/library/papers/34392831 | PubMed |
| 15 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 16 | 30537512 | Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30537512 | PubMed |
| 17 | 38047585 | INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38047585 | PubMed |
| 18 | 35395071 | Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines. | Cancer Res | 2022 | https://conductscience.org/library/papers/35395071 | PubMed |
| 19 | 33705209 | Next-Generation Endocrine Therapies for Breast Cancer. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33705209 | PubMed |
| 20 | 27717303 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27717303 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883867 | Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883867 | PubMed |
| 42658220 | Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology. | Virchows Arch | 2026 | https://conductscience.org/library/papers/42658220 | PubMed |
| 42495706 | NUPR1 in breast cancer: mechanisms and potential applications. | Front Physiol | 2026 | https://conductscience.org/library/papers/42495706 | PubMed |
| 42352933 | CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42352933 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41999452
GET https://conductscience.org/api/papers/v1/41999452/references?page=2